non-small-cell-lung-cancer

Documents about non-small-cell-lung-cancer

• First in Human Study of AZD9592 in Solid Tumors#803531ClinicalTrials.gov
• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC#811484ClinicalTrials.gov
• Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer#828984ClinicalTrials.gov
• A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)#127587ClinicalTrials.gov
• Sing-a-Lung 2.0: protocol for a multicentre randomised controlled trial to investigate the effects and mechanisms of online-delivered singing training versus usual care 6-18 months after surgical resection for non-small cell lung cancer (NSCLC).#368331NCBI PubMed Central
• Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer#374506HAL (France)
• Adonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trial#414785Europe PMC
• Improved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell lung cancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study.#785404NCBI PubMed Central
• Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC#806153ClinicalTrials.gov
• Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q#818550HAL (France)
• Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1#287531ClinicalTrials.gov
• Supplementary Material for: Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer With Sequential ALK Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature#329785Figshare
• Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial#349967ClinicalTrials.gov
• Emergence of KRAS mosaicism with multiple variants during treatment with alectinib in ALK‑positive metastatic non‑small cell lung cancer: A case report#460839HAL (France)
• A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy#802952ClinicalTrials.gov
• A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks#828415ClinicalTrials.gov
• Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis#7722HAL (France)
• Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study#14270HAL (France)
• Predictive value of baseline eosinophil counts for immune-related adverse events in metastatic NSCLC treated with immune checkpoint inhibitors#386527ARPHA OAI-PMH Endpoint
• A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment#839339ClinicalTrials.gov
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.#828040ClinicalTrials.gov
• A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer#215397HAL (France)
• Table 1_Case Report: Contrast-enhanced ultrasonography for evaluating a newly detected contralateral pulmonary lesion during non-small cell lung cancer chemoimmunotherapy.docx#210838Figshare
• Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer#429747ClinicalTrials.gov
• Correction: Malnutrition assessed by the mini nutritional assessment is associated with overall survival in patients with resectable non–small cell lung cancer / Denis I. Trufa, Koblandy Khamitov, Lena Kopplin, Horia Sirbu#675525Deutsche Nationalbibliothek
• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma#813547ClinicalTrials.gov
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers#801878ClinicalTrials.gov
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study#411390ClinicalTrials.gov
• A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors#806826ClinicalTrials.gov
• A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification#805511ClinicalTrials.gov
• Evaluating The Direct Medication Costs Associated With Advanced Non-Small Cell Lung Cancer (nsclc) Treatment By Biomarkers In The United States: A Coarsened Exact Matching Retrospective Cohort Study#260903EliScholar
• Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan’s Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer#397220Springer Nature OA
• Post-treatment serum interleukin-6 is independently associated with disease progression in patients with advanced non-small cell lung cancer and coexisting COPD: a multicenter real-world cohort study#673302ARPHA OAI-PMH Endpoint
• Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in stage IIIB-IV squamous non-small cell lung cancer: a systematic review and meta-analysis of phase 3 randomized controlled trials.#685551NCBI PubMed Central
• Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD#326525IRIS
• A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors#826788ClinicalTrials.gov
• Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26#299205Springer Nature OA
• Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)#474773ClinicalTrials.gov
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer#148580ClinicalTrials.gov
• National Cancer Institute "Cancer Moonshot Biobank"#810468ClinicalTrials.gov
• A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation#435749ClinicalTrials.gov
• A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)#802132ClinicalTrials.gov
• A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010#802106ClinicalTrials.gov
• First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)#333826HAL (France)
• The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)#417530ClinicalTrials.gov
• A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation#811036ClinicalTrials.gov
• PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes#320317IRIS
• Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance#834144ClinicalTrials.gov
• PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol#630425HAL (France)
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies#279529ClinicalTrials.gov